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Targeted nanoconjugate co-
delivering siRNA and tyrosine 
kinase inhibitor to KRAS mutant 
NSCLC dissociates GAB1-SHP2 post 
oncogene knockdown
R. Srikar1, Dhananjay Suresh2, Ajit Zambre1, Kristen Taylor3, Sarah Chapman4, 
Matthew Leevy4, Anandhi Upendran5,6 & Raghuraman Kannan1,2,7
A tri-block nanoparticle (TBN) comprising of an enzymatically cleavable porous gelatin nanocore 
encapsulated with gefitinib (tyrosine kinase inhibitor (TKI)) and surface functionalized with cetuximab-
siRNA conjugate has been synthesized. Targeted delivery of siRNA to undruggable KRAS mutated 
non-small cell lung cancer cells would sensitize the cells to TKI drugs and offers an efficient therapy 
for treating cancer; however, efficient delivery of siRNA and releasing it in cytoplasm remains a major 
challenge. We have shown TBN can efficiently deliver siRNA to cytoplasm of KRAS mutant H23 Non-
Small Cell Lung Cancer (NSCLC) cells for oncogene knockdown; subsequently, sensitizing it to TKI. In 
the absence of TKI, the nanoparticle showed minimal toxicity suggesting that the cells adapt a parallel 
GAB1 mediated survival pathway. In H23 cells, activated ERK results in phosphorylation of GAB1 on 
serine and threonine residues to form GAB1-p85 PI3K complex. In the absence of TKI, knocking down 
the oncogene dephosphorylated ERK, and negated the complex formation. This event led to tyrosine 
phosphorylation at Tyr627 domain of GAB1 that regulated EGFR signaling by recruiting SHP2. In the 
presence of TKI, GAB1-SHP2 dissociation occurs, leading to cell death. The outcome of this study 
provides a promising platform for treating NSCLC patients harboring KRAS mutation.
NSCLC is diagnosed in an estimated 220,000 patients each year with five-year overall survival rates of 16 percent1. 
A recent report confirmed that 16 percent of NSCLC patients carry oncogenic KRAS mutation2. A potent drug 
targeted against KRAS mutation has not yet been developed and the objective response rate with the current 
standard of care is just three percent. An earlier report had suggested siRNA therapy renders the undruggable 
KRAS mutant cells to become susceptible to Tyrosine Kinase Inhibitors (TKI)3. Short interfering RNA (siRNA) 
is a well-known approach for effecting gene therapy to provide subsequent sensitization towards complementary 
therapeutic agents. However, stable delivery of siRNA is a significant challenge due to its high degradation rate 
in the presence of serum proteins and enzymes. To overcome this challenge, several nanoparticle based carrier 
systems have been attempted and those include retroviral vectors, liposomes, polymeric, and metallic nanopar-
ticles3–7. In these reported studies the physicochemical and surface properties of the particle were modified for 
delivering the siRNA to cytoplasm of the infected cells. Unfortunately, these nanoparticles suffer from serious 
limitations such as stability issues during synthesis, premature release in serum, inefficient endosomal escape, 
and interferon response4,8,9. Importantly, oncogene knockdown alone has less impact on the cancer cell apoptosis 
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since the cells tend to adopt another effector pathway for survival3,10–12. Therefore, a need for complementary 
drug for initiating the apoptosis post knockdown is needed. Indeed, drugging cells separately and exogenously 
post oncogene knockdown has been reported earlier9–11. A combined delivery system wherein, co-delivery of 
a drug along with siRNA to impede growth and survival of the cell has also been attempted13. The relevance of 
the combined delivery is to ensure the complementary drug enters the same cells that are affected by siRNA at a 
predetermined appropriate proportion and time for causing cellular apoptosis. However, incorporation of siRNA 
(with minimal degradation) with a drug and a biomarker-targeting antibody into a single platform is synthetically 
challenging. Thus, stable and targeted delivery with concomitant cytotoxic action to cancer cells continues to be 
at early exploratory stages.
Significant efforts have been made to understand the downstream effect of oncogene knockdown mediated via 
siRNA till date14. Cancer cells have several parallel working pathways, with one primary effector pathway coupled to 
several parallel effector pathways15. The parallel pathways remain dormant until the working pathway is disrupted. 
Change in the protein expression levels upon knock down of oncogene present in the primary pathway results in 
change of downstream protein and gene expression levels regulated by complex cellular mechanism. This mode 
of intra-cellular functioning adaptation evolves to drug resistance within cancer cells that are previously respond-
ing to therapy16. On the other hand, KRAS mutant adenocarcinoma of NSCLC have been undruggable till date17. 
While mutations occur at variation position of KRAS, oncogenic effect at codon 12 (Glycine-12 to Cysteine, G12C) 
of KRAS is the most commonly occurring mutation and yet to receive a dedicated drug18. Although, in recent 
times, few attempts have been made for targeting G12C mutation through a small molecule inhibitor, RNAi therapy 
is emerging as a promising tool that could be applied across all types of mutations supplemented with currently 
approved drugs19,20. For example, knocking down a specific gene of undruggable cancer, such as KRAS mutant ade-
nocarcinoma of NSCLC, can activate a parallel dormant effector pathway that may be sensitive to a TKI3.
In this work, we report the synthesis and utilization of gelatin nanoparticle (Gel NP) as a carrier system encap-
sulated with gefitinib (GelGEFNP). The Gel NP is surface functionalized with cetuximab (Ab), a EGFR targeting 
antibody, conjugated to KRAS G12C specific siRNA (Ab-siRNA conjugate) (Fig. 1). KRAS G12C specific siRNA 
is chemically conjugated to cetuximab by thio-ether linkage. Cetuximab antibody target EGFR receptor on the 
cells and also protects siRNA from external degradation. We believe the 14 kDa siRNA is camouflaged by 146 kDa 
cetuximab antibody thus remaining un-exposed to external environment. The knockdown of oncogene upon 
treatment with TBN was confirmed by studying downstream signaling events studying protein expression levels, 
and the effect of sensitization towards drug molecule was determined by in vitro cytotoxicity assays. A possible 
mechanism governed by GAB1 mediated downstream signaling as an adopted pathway post oncogene knock-
down has been shown. Change in expression levels of two cytoplasmic genes confirming oncogene knockdown 
and the mechanism of sensitization towards a TKI due to the adopted effector pathway is reported in this study.
Results
Synthesis of Tri-block Nanoparticle (TBN). Gefitinib encapsulated Gel NPs (GelGEFNP) were prepared 
using two-step desolvation method21,22. GelGEFNP was washed several times to ensure no diffusion or desorption 
mediated release of gefitinib occurs and that any release occurring from the nanoparticles is attributed only 
to degradation assisted release mechanism. For conjugating cetuximab monoclonal antibody on the surface of 
GelGEFNP, carboxyl groups present on the surface were converted to reactive NHS ester followed by addition of 
antibody. The amine groups present in antibody reacted to the modified carboxyl group enabling the conjugation 
of the antibody to GelGEFNP. Subsequently, amine-thiol linker sulfo-SMCC, was used to convert amino groups on 
the antibody to thiol reactive maleimide group. KRAS specific siRNA with 5′ sense strand modified with disulfide 
Figure 1. (a) Schematic representation of tri-block nanoparticle (TBN) consisting of gelatin nanoparticle 
encapsulated with gefitinib and surface functionalized with cetuximab conjugated siRNA; (b) TEM image of 
Gelatin Nanoparticles; and (c) TEM image of TBN.
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end group was reacted to maleimide present on the antibody for the preparation of antibody-siRNA conjugate, 
thus forming the tri-block nanoparticle (TBN) (see supplementary information Figures S-1 and S-2).
Characterization of Tri-block Nanoparticle. Physical properties of Gel NPs prepared via desolvation 
process conformed to earlier reports21,22. Gel NPs dispersed in DI water indicated an average hydrodynamic 
diameter of 225 ± 20 nm with a polydispersity index (PDI) less than or equal to 0.1. Zeta potential (ζ ) measure-
ments of Gel NPs suspended in DI water showed a positive value of + 19 mV (± 2). As expected, the size and ζ 
did not change with gefitinib encapsulation indicating surface properties of Gel NPs remain unchanged with 
encapsulation (see supplementary information Figure S-3). TEM image analysis displayed a core size similar to 
the measured hydrodynamic diameter (~200 nm) (Fig. 1).
To determine the encapsulation efficiency of gefitinib within Gel NPs and percent of drug loading, UV-Vis 
absorption spectroscopy was used. In this experiment, GelGEFNP at known concentration dispersed in DI water 
and subjected to protease degradation. The translucent solution turned transparent after 1 hour indicating 
digestion of gelatin matrix. To ensure that the particles are completely degraded, the solution was centrifuged 
at 20,000 g for 20 minutes and absence of precipitate indicated complete degradation of the matrix. The solution 
was then passed through 0.2 μ m filter and the filtrate was analyzed for characteristic 331 nm absorption peak of 
gefitinib23. Gefitinib calibration curve was used as reference. Analysis revealed 40% encapsulation efficiency with 
5 μ g of gefitinib per mg of Gel NPs (0.5% loading, post all release including burst release and diffusion/desorption 
mediated release).
To determine the amount of monoclonal antibody, cetuximab, conjugated to the surface of Gel NPs or 
GelGEFNPs, Bradford protein estimation assay was used. The assay showed that 45 (± 5) μ g of cetuximab was 
conjugated per mg of Gel NPs. The percentage of antibody conjugation, in other words, conjugation efficiency 
changed proportionally with the relative initial amount of nanoparticles (Gel NPs or GelGEFNPs) for all 5 exper-
iments carried out for reproducibility (amount of cetuximab was kept constant at 1200 μ g). However, amount of 
antibody conjugated per mg of nanoparticles remained constant at 45 (± 5) μ g per mg of Gel NPs or GelGEFNPs. 
The hydrodynamic size of the antibody-conjugated nanoparticles (Ab-Gel NPs or Ab-GelGEFNPs) did not show 
any significant change and was found to be 225 (± 15) nm. TEM images however appeared relatively well resolved 
in the case of Ab-Gel NPs/GelGEFNPs compared to that of Gel NPs or GelGEFNPs. (Fig. 1 and Figure S-2) This 
could be due to the increased surface density of the nanoconstruct leading to a relatively higher contrast for the 
Ab-GelGEFNPs compared to that of Gel NPs or GelGEFNPs. The ζ of Gel NPs and Ab-Gel NPs, however, showed 
a drastic change post surface modification; for example, the ζ changed from + 18 mV to − 12 mV confirming 
alteration on the surface (Figure S-3).
To estimate the concentration of siRNA loaded on the Gel NP or GelGEFNP, florescence spectroscopy was used. 
In this experiment, Cy5 labelled siRNA was used as a surrogate to estimate the loading of siRNA. After conju-
gation reaction, the supernatant after centrifugation (20,000 g, 20 mins) was analyzed for characteristic 660 nm 
emission peak of cy5 using florescence spectroscopy. Using the manufacturer’s extinction coefficient (367,569 L.
mol−1.cm−1), the fluorescence signal obtained was compared with reference curve of siRNAcy5 and the conjuga-
tion of siRNA on the nanoparticle was determined to be ~98%. Visual observation of characteristic blue color of 
Cy5 present on the nanoparticle pellet and absence of the color in the supernatant also confirmed the high siRNA 
conjugation qualitatively (see supplementary information Figure S-4). Absolute number of siRNA, antibodies and 
TKIs per Gel NP is listed in Table S-1.
Stability of Tri-block Nanoparticle. To estimate the serum stability of unmodified siRNA and siRNA con-
jugated to the nanoparticle, we utilized native polyacrylamide gel electrophoresis (PAGE) technique as reported 
previously24. The nanoparticles with appropriate controls including naked siRNA and Ab-Gel NP were added to 
10% serum solution at 37 °C. At predetermined time intervals (0, 0.5, 1, 2, 4, 8 and 24 hr), 100 μ l of each sample 
was removed and stored at − 50 °C. The solutions were thawed to room temperature and subjected to native 
PAGE; the presence of siRNA was detected using nucleic acid staining GelRed dye (Fig. 2a). The use of thio-ether 
bond for conjugating siRNA to the antibody present on the gelatin nanoparticles renders it uncleavable from 
the nanoconstruct25. Any gelatin degradation agent such as protease or antibody disruption would have adverse 
effect on siRNA quality and indicate false-negative results. Therefore, the stability study of the siRNA was based 
on the direct GelRed nucleic acid staining of the siRNA present on the nanoparticle as reported earlier26. Naked 
siRNA and Ab-Gel NPs/GelGEFNPs were used as controls to evaluate the 24 hr stability of siRNA. Unbound or 
electrostatically bound siRNA to nanoparticles had degradation profile similar to naked siRNA. However, siRNA 
conjugated to nanoparticles were highly stable with minimal degradation for 24 hours. In addition, 30 days stabil-
ity analysis of the nanoparticle stored at − 50 °C showed minimal degradation (Fig. 2b). In vitro stability studies 
of TBN as analyzed by hydrodynamic size in biological media containing 10% serum showed no significant vari-
ations in the diameter of the nanoparticles until 24 hr time points (Fig. 2c).
Cellular Internalization of Tri-block Nanoparticle. To understand the cellular internalization capability, 
we used Gel NP encapsulated with fluorescein (fl) dye (GelflNP) and siRNA labeled with cy5 dye (siRNAcy5) for 
detection using two different fluorescent signals. The internalization study was performed in H23 cancer cell line 
and analyzed using fluorescence microscopy (Fig. 3). Indeed, co-localization of siRNAcy5 and GelflNP was con-
firmed by two fluorescence signals emanating from cells. To estimate the relative amount of siRNA internalization 
within cells, we performed flow cytometry analysis. In this experiment, we incubated H23 cells independently 
with (i) siRNAcy5 along with transfecting agent (TA-siRNAcy5); (ii) Gel NP-Ab-siRNAcy5; or (iii) Ab-siRNAcy5 for 
4 hours (Fig. 4). After 4 hours, the cells were repeatedly washed to remove surface adhered molecules and were 
trypsinized. Subsequently, the cells were analyzed using flow cytometry and the results showed internalization 
in the following order: Gel NP-Ab-siRNAcy5 > TA-siRNAcy5 > Ab-siRNAcy5. As expected, the amount of siRNA 
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internalized through nanoparticle was at least two fold higher than transfected siRNA (Fig. 4). Results showed the 
superiority of TBN as an effective siRNA delivery system.
Knockdown Mediated Protein Regulation. It is important to ensure that internalized nanoparticle is 
present in the cytoplasm and knocks down the KRAS gene as intended and regulates the appropriate protein 
levels. In order to understand downstream protein level regulation before and after oncogene knockdown, we 
used H23 cell line harboring KRAS mutation at G12C. In this experiment, we studied the effect of TBN on RAS/
RAF/MEK/ERK cascade, a complex signal transduction pathway that has been extensively studied and mapped27. 
Untreated H23 cells exhibits phosphorylated downstream proteins in two effector pathways. In first pathway, RAS 
activates downstream effector enzymes enabling cell proliferation and survival through phosphorylation of RAF. 
This phosphorylation in-turn activates mitogen activated protein kinase (MEK/MAPK) that is responsible for 
activation of ERK. In second effector pathway, RAS has been found to activate PI3K effector pathway leading to 
phosphorylated AKT15. PI3K/AKT signaling network that runs parallel to RAS/MAPK pathway is known to have 
several points of interaction with each other influencing inter-signal transduction15. Therefore, disruption of RAS 
with oncogene knockdown should result in downregulation of primary downstream protein pMEK as well as 
parallel pathway protein pAKT. Indeed, the results indicate a direct intrinsic relation between the two pathways 
primarily governed by RAS (Fig. 5). Similar results were obtained in previous studies; for example, oncogene 
knockdown using retroviral shRNA in H23 resulted in significant reduction of downstream-activated proteins 
including pMEK, pERK and pAKT3. In addition to the above pathways, it is also interesting to know the status 
of EGFR in these KRAS mutation cell lines. Previous studies have already established that mutations in KRAS 
and EGFR are mutually exclusive28. Therefore, all EGFR downstream proteins will largely be dormant. However, 
a recent study showed that post knockdown of KRAS oncogene showed the presence of pEGFR within three 
days suggesting activation of EGFR to compensate for the loss of KRAS oncogenic activity3. Similarly, inhibition 
of activated ERK sensitized TKI resistant cells towards gefitinib29. Another report suggested a similar outcome 
wherein, blocking PI3K and MAPK signaling pathways led to gefitinib sensitization for TKI resistant NSCLC30. 
Even though progress has been made to unravel the underlying mechanism that enables sensitization of KRAS 
cells towards TKIs, it remains largely inconclusive. In this regard, Wu and coworkers recently reported the dis-
sociation of “SHP2-GAB1” proteins within KRAS mutant cells, when treated with erlotinib31. The study further 
showed inhibition of GAB1 tyrosine phosphorylation in HCC827 cells, a TKI responsive cell line, when treated 
with erlotinib. Based on these studies, we focused to investigate a possible GAB1 mediated survival pathway in 
the case of treatment of TBN with H23 cell line. Our results showed that GAB1 and pGAB1 at Tyr 627 was 
found to be upregulated upon treatment with TBN while no substantial difference was found for pGAB1-307 
(supplementary information Figure S-5). Also, SHP2, pSHP2 (Y542) and pSHP2 (Y580) remained unchanged 
for Gel NP (without gefitinib) but was found to be downregulated in the presence of gefitinib for the cells 
Figure 2. Stability of siRNA and TBN in serum. (a) Serum stability with time was analyzed using native PAGE, 
the results reveal that siRNA present on TBN are highly stable. Lane description – 1: 0 hr; 2: 0.5 hr; 3: 1 hr; 4: 2 hr; 
5: 4 hr; 6: 12 hr; 7: 24 hr; and 8: naked siRNA at 0 hr in DI water. The lower band in lane 1 corresponds to free 
siRNA and siRNA cleaved from Tri-block nanoparticle (TBN) by serum solution. The band disappears within 30 
min. indicating the short stability of free siRNA in serum; (b) Long term siRNA stability analysis of nanoparticle 
stored at − 50 °C in presence of cryoprotectant; and (c) In vitro stability of TBN in biological media containing 
10% serum at various time points analyzed by measuring hydrodynamic diameter of nanoconstruct.
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transfected with siRNA or treated with TBN (Fig. 6). Considering the downstream protein regulation was 
significantly altered through siRNA mediated gene therapy, we extended our investigation in understanding 
whether TBN would render the cells susceptible to TKI.
Efficacy of Tri-block Nanoparticle. Considering downregulation of downstream-phosphorylated pro-
teins, our next step was to investigate the cell viability of H23 cells (MTT assay) after knocking down RAS 
pathway. For comparison of various individual components of the nanoparticle, toxicity data was normalized 
with gefitinib concentration and the corresponding concentration of appropriate controls are shown in the 
Figure 3. Cellular localization of TBN in H23 cells. Florescence microscopy of H23 cells incubated with TBN 
(GelFlAb-siRNACy5) and its analogues GelFlAb-siRNA, Gel-AbCy5-siRNA, Gel-Ab-siRNACy5, siRNACy5 and AbCy5. 
DAPI was used as a nuclear staining marker. Fluorescein was used for encapsulation in Gelatin Nanoparticles. 
Cy5 was used for labelling antibody and siRNA. The figure shows co-localization of cy5 labelled siRNA and 
fluorescein encapsulated gelatin nanoparticles in H23 cells. Appropriate controls with and without fluorescein 
or cy5 were used. All images were recorded at 20X magnification.
www.nature.com/scientificreports/
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supplementary information Figure S-6. IC50 value of gefitinib for H23 cell lines was determined to be 50 μ M. 
Interestingly, transfected siRNA (4 μ M, dose corresponding to 50 μ M gefitinib) did not cause any cytotoxicity 
and the viability of the cells remained 100% suggesting oncogenic disruption alters effector pathway but does not 
lead to apoptosis. On the other hand, when we used TBN the IC50 value drastically reduced by 20 fold to 2.5 μ 
M, and complete loss of cell viability was found for nanoparticle containing 5 μ M of gefitinib (Fig. 7). A similar 
cytotoxicity trend was found when H23 cells were transfected with siRNA and gefitinib was added exogenously. 
The controls used for cytotoxicity assay include gefitinib, transfected siRNA with and without gefitinib (siRNA 
(TA)+ gef, siRNA (TA)), cetuximab (Ab), cetuximab-siRNA (Ab-siRNA) with and without gefitinib, gelatin nan-
oparticles (Gel NP), gefitinib encapsulated gelatin nanoparticles (GelGEFNP), and mock siRNA with gefitinib (see 
supplementary information Figures S-7–S-9). No significant changes in toxicity relative to nanoparticle were 
found in the case of controls.
Gene Regulation. To understand the effect of siRNA knockdown and protein down-regulation on the effec-
tor pathway adopted for survival of cells, we performed quantitative real time PCR by examining dual specificity 
phosphatase 6 (DUSP6) and CD73 gene expression levels. Earlier reports have indicated that DUSP6 expression 
is regulated by ERK signaling in RAS/RAF/MEK/ERK cascade32. Also, DUSP6 is an important feedback loop as 
it exhibits antitumor profile through negative feedback regulation33. An effect on the signaling cascade, therefore, 
must have an effect on DUSP6 levels. Transfected siRNA and TBN showed downregulation of DUSP6 upon 
knockdown. The RF values of DUSP6 post knockdown determined using real time qPCR for nanoparticle corre-
lated well with that of transfected siRNA and was determined to be 0.17 and 0.1 for TBN and siRNA respectively. 
In contrast, Ab-GelGEFNP devoid of siRNA, showed the RF value of 0.73 indicating minimal or no effect on the 
gene regulation. The results suggest post oncogene knockdown, loss of activity in the MEK/ERK cascade has a 
direct impact on the gene regulation of DUSP6 (Fig. 8a). NT5E or CD73 is a gene that has shown relevance as a 
predictive biomarker for overall survival and progression free survival in human patients harboring KRAS wild 
type or KRAS mutation. In another study, NT5E transfected breast cancer T-47D cells resulted in increased levels 
of cell migration and invasion34. Also, significant increase in protein expression levels of EGFR was observed 
post transfection. It was also found that CD73 expression is directly proportional to EGFR expression and sup-
pression of EGFR resulted in decreased CD73 levels. These observations led us to investigate the CD73 gene level 
Figure 4. Flow cytometry analysis. Flow cytometry analysis reveals GelNP-Ab-siRNAcy5 internalizes almost 
2 folds compared to transfected siRNA. Cetuximab-siRNA (Ab-siRNA), on the other hand, has minimal 
internalization relative to other compounds.
www.nature.com/scientificreports/
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expression for understanding the mechanism post loss of activity on RAS/RAF/MEK/ERK cascade after siRNA 
mediated knockdown. Interestingly, we observed a significant increase in the CD73 expression levels for cells 
treated with TBN and no change for the cells transfected with siRNA or treated with Ab-GelGEFNP devoid of 
siRNA. The CD73 RF value for cells treated with TBN was determined to be 3.64 compared to 1.07 and 0.95 for 
siRNA and Ab-GelGEFNP with no siRNA respectively (Fig. 8b). The increase in CD73 expression levels could be 
attributed to presence of both siRNA and cetuximab in TBN.
In summary, based on the collective data obtained we were able to predict the mechanism of release of TBN 
from endosomes to cytosol (Figure S-10) and the concomitant effect of gene and protein regulation. As an addi-
tional control, we studied the effect of siRNA and TBN in A549 NSCLC cells that has KRAS G12S mutation 
(Figure S-11). It is worth to note the siRNA that we used in our present study is targeted for G12C mutation. 
Based on the cell viability data, it is evident that siRNA and TBN is very specific for KRAS G12C mutation and 
have minimal or no effect of G12S mutation. The results further confirm the specificity of the conjugate toward 
particular mutation.
In vivo dose safety study. We performed a preliminary evaluation of in vivo safety of the TBN in normal 
mice. The safety study was conducted in five normal mice by repeated intravenous (IV) injection of the nanocon-
struct (80 mg/Kg body weight) for three consecutive days, followed by euthanasia. Subsequently, major organs were 
collected and histopathology was performed. The data showed that animals did not show any abnormal behavior, 
and histology analysis indicated no signs of toxicity showing tolerance of injected dose in animals (Figure S-12).
Discussion
We synthesized a targeted TBN as an effective siRNA delivery system to sensitize the KRAS mutant tumor cells 
to gefitinib. The study demonstrated that camouflaging siRNA between gelatin and antibody molecules in TBN 
increased the stability of the siRNA. Indeed, serum stability and cytoplasmic delivery of siRNA present within 
TBN are attributed to synergistic effect of both Gel NP and cetuximab antibody. The release of encapsulated 
gefitinib from TBN primarily governed by degradation of gelatin matrix of the nanoparticle; however, exposure 
Figure 5. (a) Western Blot analysis showing the effect of KRAS mutant knockdown by transfection agent or 
through TBN and gefitinib on the phosphorylation of MEK, AKT, EGFR in the KRAS mutation positive NSCLC 
cell line; (b) A graphical representation using densitometry image analysis, showing the protein expression 
levels after KRAS knockdown. The data were obtained from three independent experiments.
www.nature.com/scientificreports/
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or release of siRNA to form RNA-induced silencing complex (RISC) can occur in two ways, either through the 
surface degradation of Gel NP that subsequently releases Ab-siRNA conjugate forming RISC or via direct com-
plexation of RISC with siRNA present on the nanoparticle (Figure S-10). However, determining the dominant 
mechanism that is responsible for complexing with RISC is difficult to detect or predict.
As reported in the literature, siRNA mediated mutant KRAS oncogene knockdown results in down regulation 
of phosphorylated proteins present downstream of RAS pathway3. In our study, we observed a similar trend, 
wherein pMEK present in RAS pathway was downregulated by mutatnt KRAS oncogene knockdown. In com-
parison with untreated cells, the relative down regulation of pMEK was found to be at least 2 times lower when 
we used TBN. As expected, the down regulation of the downstream proteins mediated by TBN showed similar 
response as that of transfected siRNA. Gel NP without siRNA had no effect on pMEK, thereby proving that 
knocking down KRAS oncogene effectively decreases RAS functioning pathway. Also, RAS/MEK/ERK pathway 
is known to be closely associated to PI3K/AKT pathway. With 802 interactive proteins involved in PI3K signaling 
and over 2000 proteins in the case of MAPK pathway, several cross talk points exist between PI3K/AKT and RAS/
MAPK pathway15. Among these proteins, Grb2 associated binder-1 (GAB1) has been identified as an important 
Figure 6. Gefitinib induced protein regulation. (a) Treatment on KRAS mutated H23 cells by transfected 
siRNA and siRNA delivered using TBN did not show any effect on SHP2 and p-SHP2. However, in the presence 
of gefitinib, pSHP2 (Y542), pSHP2 (Y580) and SHP2 protein were downregulated indicating impaired SHP2 
function – a probable cause of H23 cell apoptosis after oncogene knockdown; (b) Densitometry image analysis 
using BioRad Image lab V.3 was carried out to quantify the proteins.
Figure 7. In vitro cytotoxicity. Cytotoxicity data indicates nanoparticle treatment knocks down oncogene and 
sensitizes KRAS mutant H23 cell line towards gefitinib. The cell viability of TBN at 5 μ M gefitinib concentration 
is 5% compared to 25% viability for cells transfected with siRNA followed by gefitinib treatment.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:30245 | DOI: 10.1038/srep30245
adaptor protein playing central role in various cell responses35,36. Specifically, GAB1 is found to be functionally 
active docking protein for several downstream signaling pathways including EGFR. PI3K and GAB1 share intrin-
sic association via tyrosine domain phosphorylation of GAB1 on SHP2 binding motifs. SHP2 negatively regulates 
PI3K activation through dephosphorylation of GAB1 phosphotyrosinases facilitating the activation of RAS for 
certain cases37. In others, activated ERK results in phosphorylation of GAB1 (Grb2 associated binder 1) on serine 
and threonine residues adjacent to p85 PI3K binding sites and the nature of signaling dictates regulation levels of 
GAB-p85 PI3K complexes to control PI3K activity15. In the case of H23 cells, we found that pAKT reduced with 
downregulation of pMEK and pERK. The result suggests that the feedback loop of MAPK with PI3K is possibly 
governed by GAB1 phosphorylation on serine and threonine residues and not via SHP2-PI3K binding prior to 
RAS oncogene knockdown. The silencing of activated ERK signaling by RAS oncogene knockdown disrupts 
the formation of GAB-P85 PI3K complex by negatively affecting serine and threonine phosphorylation levels 
of GAB1. This negative feedback results in arresting PI3K pathway and downregulating AKT activity in the case 
of H23 cells. A similar result was reported previously, that is ERK positively regulate GAB1 p85 interaction; 
subsequently inhibiting ERK and result in decreased AKT activity38,39. It is known that ERK regulation of GAB 
P85 PI3K complexes is mediated by Hepatocyte Growth Factor (HGF)35. The fact that HGF is highly expressed 
in the case of H23 cells strengthens our claims that ERK induces positive regulation of GAB1 for associating with 
P85-PI3K via HGF mediation under normal conditions, disruption of which deactivates PI3K/AKT pathway40,41.
Interestingly, there was no effect on cell viability with 100% cell survival with disruption of RAS/MEK/ERK 
pathway post RAS oncogene knockdown (for both transfected siRNA and Gel NP without gefitinib). Addition of 
gefitinib to siRNA treated cells, however, showed considerable effect on the viability of the cells, more so for the 
TBN compared to transfected siRNA. The results corroborate well with an earlier report wherein, Hoeben et al. 
showed inhibition of GAB1 activity in head and neck squamous cell carcinoma reduced signaling of EGFR result-
ing in sensitization of the cells towards gefitinib42. Several other studies have shown intricate relationship existing 
between tyrosine kinase inhibitors and disruption of MAPK/PI3K pathways30,43,44. However, the question that still 
needs to be addressed is the functional mechanism of the H23 cells for survival with knocked-down RAS onco-
gene, and in effect, with arrested MAPK and PI3K pathways. As mentioned earlier, tyrosine phosphorylation of 
GAB1 can effectively associate with EGFR. With inability of GAB1 to form complexes with p85 PI3K due to loss 
in serine phosphorylation, GAB1 can effectively regulate EGFR signaling through several positive feedback loops. 
One possibility is that association of GAB1 with EGFR by recruiting SHP2 and cascading EGFR downstream sig-
naling. In the case of downstream EGFR, SHP2 is activated by complexing with phosphorylated GAB1 that binds 
with EGFR through Grb2. Tyr 627 domain is one of the predominant domains of pGAB1 wherein the complexing 
occurs45. Indeed, western blot results indicated an increase in the pGAB1 (Tyr 627) after oncogene knockdown 
by TBN supporting our hypothesis that knockdown of KRAS oncogene arrests MEK/ERK pathway, triggering a 
feedback loop wherein GAB1 dephosphorylation on serine and/or threonine residues occur, resulting in abro-
gation of AKT activity. The stimulation cascades to phosphorylation at tyrosine domains of GAB1 that induces 
association of GAB1 to EGFR through SHP2 recruitment. It is thus possible that the adopted effector pathway of 
survival post oncogene knockdown is governed through EGFR downstream signaling via disrupted MAPK path-
way. It is noteworthy to mention that SHP2 regulation has intrinsic relation with tyrosine kinase inhibitors. It has 
been reported that impaired SHP2 functioning or altered localization of SHP2 causes sensitivity to gefitinib31,46,47. 
In our case, the results suggest that alteration of SHP2 localization caused by recruitment through GAB1 causes 
disruption of EGF downstream signaling. Addition of gefitinib impairs the functioning of SHP2 and disables 
complex formation with GAB1, thereby abrogating the already disrupted MAPK pathway, leading to apoptosis 
of the cells (Fig. 9).
Figure 8. RT-PCR analysis. (a) RF values determined by quantitative real time PCR indicates down regulation 
of DUSP6 gene expression for the H23 cells treated with siRNA and TBN; (b) RF values determined by 
quantitative real time PCR indicates up regulation of NT5E gene expression for the H23 cells treated with TBN. 
Cells treated with siRNA or cetuximab functionalized gelatin nanoparticles showed minimal or no change in 
expression levels compared to the untreated cells.
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In view of the pathway being governed by EGFR signaling for cells with knocked down mutant RAS oncogene, 
it was of interest to understand the behavior of gene regulation considering the nanoparticle contains cetuxi-
mab, an EGFR inhibitor. Transfected siRNA, however, could serve as a positive control in terms of oncogene 
knockdown but a negative control for EGFR blocking. Conversely, nanoparticle without siRNA could serve as a 
positive control for EGFR blocking and as negative control for oncogene knockdown. Understanding the effect of 
cetuximab could further explain the underlying mechanism as well as strengthen our earlier hypothesis. DUSP6 
is a cytoplasmic gene that plays a pivotal role in the spatiotemporal mechanism of ERK signaling48. Our results 
obtained using RT-qPCR upon oncogenic knockdown of mutant RAS showed downregulation of DUSP6 and 
the expression of ecto-5′ -nucleotidase (NT5E, also known as CD73) remains unchanged. The downregulation 
of DUSP6 is possibly due to inhibition of ERK based on several negative feedback mechanisms. Indeed, siRNA 
mediated knockdown affects the ERK pathway leading to the regulation of cytoplasmic genes. However, the effect 
of EGFR signaling on the gene regulation levels post oncogenic loss need to be monitored. CD73 is a 70 kDa cell 
surface protein that plays an important role in physiology and pathophysiology of cells. A recent report portrayed 
the importance of CD73 in relation to EGFR; wherein, it was reported that the CD73 positively regulates EGFR 
expression levels34. In our study, we observed that CD73 expression levels remain unchanged with siRNA knock-
down mediated by routine transfection as well as for Ab-GelGEFNP with and without siRNA. The result is in agree-
ment with those obtained through protein regulation studies, since the mere knockdown using siRNA causes 
no impedance to EGFR which in turn causes no change in cellular mechanism operating under RAS/MAPK 
pathway, and therefore are independent of EGFR signaling. However, cells transfected with the TBN are rendered 
susceptible to change in mechanism as well as EGFR dependent signaling causing imbalance of receptor tyrosine 
kinases. For balancing the requisite EGFR expression, CD73 is overexpressed to compensate for the loss of EGFR 
Figure 9. Effect of siRNA and Gefitinib on downstream protein regulation mechanism. (a) Effector pathway 
in the presence of oncogenic RAS mutation in H23 cells; (b) disruption of RAS downstream through siRNA 
mediated oncogene knockdown affects regular functioning of RAF/MEK/ERK pathway leading disrupted 
functioning through MAPK pathway caused by alerted localization of impaired SHP2; and (c) Addition of 
gefitinib impedes the recruitment of SHP2 by GAB1 leading to the abrogation of the already disrupted MAPK 
pathway and eventual apoptosis of the affected cells.
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caused by the nanoparticle. It is evident that standalone siRNA and cetuximab do not influence CD73 expression 
levels. Correlating these results, increased level of CD73 activity suggests a synergistic effect of cetuximab and 
oncogene knockdown. In the case of siRNA transfected cells, albeit there was loss of activity in RAS pathway, a 
parallel effector pathway governed by EGFR could have been adopted by the cells for survival. However, the nan-
oparticles experience EGF receptor mediated endocytosis for siRNA delivery, subsequent oncogene knockdown 
accompanied with loss of activity in the primary effector pathway. The simultaneous disruption of several inter-
dependent pathways and downstream effector proteins, i.e. RAS/MEK/ERK, PI3K/AKT, GAB1 and SHP2, could 
be the reason for significant change in cellular gene & protein expression levels leading to sensitization towards 
small molecule tyrosine kinase inhibitor.
Conclusion
The tri-block nanoparticle platform developed in our study, siRNA conjugated to antibody surface functionalized 
on gelatin nanoparticles carrying small molecule tyrosine kinase inhibitor, has great potential in siRNA mediated 
therapy. Interestingly, the platform protects siRNA from degradation and targets the delivery of siRNA to the 
desired biomarker. Also, the gelatin nanoparticles, used as the carrier system, enable concomitant delivery of drug 
within the cells of interest. The platform allows loading predetermined and proportional amounts of antibody, 
siRNA and drug within the carrier for effective targeting and high bioavailability to provide gene and combina-
tional therapy. Using this platform as a therapeutic drug, we found that GAB1 plays a crucial role in the absence 
of gefitinib for cell survival even after oncogene knockdown. We also found that mutant KRAS oncogene knock-
down impairs and alters the localization of SHP2 abrogating its complex formation with GAB1 in the presence 
of gefitinib leading to the apoptosis of the affected cells. Preliminary in vivo safety studies in mice showed TBN 
is safe to inject with minimal or no toxicity to major organs. It is noteworthy to mention that platform delivery 
system reported in the work can be modified as per patient needs wherein the siRNA, antibody and the encap-
sulated drug can be changed with their respective counterparts depending upon the nature and status of cancer.
Materials and Methods
Synthesis of Gelatin Nanoparticles. Two step desolvation process was used for preparing Gelatin 
nanoparticles. 500 mg of Gelatin type A (bloom 300) was first dissolved in 10 ml of De-Ionized (DI) water at 
50 °C and subjected to first desolvation using rapid addition of acetone (20 ml). The precipitate was dissolved in 
10 ml DI water (pH 2.75) and second desolvation using dropwise addition of acetone (3 ml/min) was initiated. 
Transformation of the transparent solution to milky white solution indicated successful desolvation and forma-
tion of nanoparticles. After 10 minutes, the nanoparticles were cross-linked with 200 μ l of 25% glutardehyde. The 
reaction was allowed overnight at 50 °C and the resulting nanoparticulate solution washed 5 times with DI water 
to remove excess glutaraldehyde (20,000 g for 45 minutes per wash). For the preparation of gefitinib encapsula-
tion, 1 mg of gefitinib hydrochloride dissolved in DI water was added during the second desolvation process prior 
to acetone addition. The nanoparticles were then resuspended in DI water and stored at 4 °C.
Cetuximab Conjugation. The carboxyl groups present on the surface of the Gel NPs and GelGEFNPs were 
activated using EDC/NHS reaction. 10 mg of gelatin nanoparticles were suspended in MES buffer (pH 4.5) at a 
concentration of 5 mg/ml. Activation was performed at room temperature for 3.5 hours under constant shaking 
(850 RPM). The activated nanoparticles were washed to remove excess EDC/NHS (20,000 g for 20 minutes). The 
activated particles were resuspended in 2 ml PBS (pH 6.7–7.0) containing 600 ul of cetuximab (2 mg/ml) and the 
reaction was allowed to incubate overnight at room temperature under constant shaking (850 RPM). The particles 
were then washed to remove the supernatant containing unreacted antibody. The antibody functionalized par-
ticles (Ab-Gel NP) were re-suspended in PBS and stored at 4 °C. Excess antibody through centrifugal separation 
was analyzed for antibody quantification using Bradford assay with appropriate controls and standards.
siRNA functionalization. Sulfo-SMCC (0.75 mg) was dissolved in 0.5 ml DI water and added to Ab-Gel 
NPs or Ab-GelGEFNPs (7.5 mg suspended in 1X PBS). The pH of the solution was maintained at 6.7–7.0. The reac-
tion was allowed for 3.5 hours at room temperature and the excess sulfo-SMCC was removed through washing 
as described previously for EDC/NHS removal. The nanoparticle solution, post conversion of lysine residues on 
antibody with the SMCC linker, was resuspended in RNAse free water and 0.05 ml of 50 μ M thiol modified siRNA 
was added to the solution for linking the maleimide end of the linker to the thiol end of the siRNA. The reaction 
was allowed overnight at 4 °C under constant shaking at 500 RPM. The solution was used immediately for further 
experiments. For quantification of bound siRNA, Cy5 labelled thiol modified siRNA was used. For determining 
the long-term stability of siRNA within the construct, 5% sucrose (wt. of sucrose/wt. of Gel NP) was added to the 
TBN and stored at − 50 °C.
Cetuximab quantification. Amount of cetuximab conjugated to TBN was determined by quantifying the 
amount of unconjugated cetuximab present in the supernatant after the conjugation reaction. For example, 20 μ l 
of the supernatant and 20 μ l of standards (cetuximab, 2 mg/ml serially diluted till 0.03125 mg/ml) were inde-
pendently pipetted in 96 well plate. 200 μ l Biorad Bradford reagent was added to each of this well and incubated 
at room temperature for 30 minutes. Intensity of color developed through interaction of the antibody and the 
reagent was measured using Biotek Cytation 3 spectrophotometer at wavelength of 595 nm and the amount of 
cetuximab conjugated to the nanoparticles was back calculated and determined.
Gefitinib Quantification. Estimation of amount of gefitinib encapsulated within the TBN was carried out 
using absorption spectroscopy. 1 ml of the synthesized TBN containing 1 mg/ml of gelatin nanoparticles was 
completely degraded using 2 mg/ml of protease. The degraded solution was centrifuged at 20,000 g for 30 minutes 
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to ensure no precipitation of particles. The solution was then passed through 10 kDa Amicon filters (10000 g for 
10 minutes) the filtrate was characterized for determining the gefitinib content using absorption spectroscopy at 
331 nm. Gefitinib standard curve was then used to determine the concentration of the analyzed filtrate.
siRNA quantification. Estimation of siRNA present in TBN was determined through florescence spectros-
copy. After the addition of 50 μ M siRNA tagged with cy5 dye, the reaction was allowed to proceed as detailed 
above. 1 ml of TBN containing 50 μ M of siRNAcy5 was then centrifuged at 20,000 g for 20 minutes and the super-
natant was analyzed for unbound siRNA. The analysis was carried out in 96 well plate containing 100 μ l of sample 
(triplicate). The excitation and emission of the dye were 646 nm and 660 nm respectively. Biotek cytation 3 spec-
trophotometer was used for the analysis.
In vitro cytotoxicity assay. H23 human adenocarcinoma non-small cell lung cancer cells (ATCC, USA) 
and A549 human adenocarcinoma epithelial cells (ATCC, USA) were grown in RPMI 1640 medium supple-
mented with 4.5 g/L D-glucose, 25 mM HEPES, 0.11 g/L sodium pyruvate, 1.5 g/L sodium bicarbonate, 2 mM 
L-glutamine, 10% heat-inactivated fetal bovine serum (Altlanta Biologicals, USA) and 0.1% v/v gentamycin. Cells 
were cultured in a humidified atmosphere of 95% air and 5% CO2 at 37 °C (Thermo Scientific, USA). For deter-
mining in vitro cytotoxicity, MTT assay was performed by incubating various samples including the nanoparticle 
of interest on H23 and A549 cells. The concentrations were normalized with respect to gefitinib concentration 
for all samples (50 μ M, 5 μ M, 0.5 μ M, 0.05 μ M, 0.005 μ M 0.0005 μ M and 0 μ M). For samples that did not contain 
gefitinib, weight of gelatin nanoparticles was used for normalization. Each sample was analyzed in triplicate. After 
24 hours of incubation, 10 μ l of MTT solution (ATCC, USA) was added and the plate was incubated at 37 °C for 
4 hours. Crystals formed were dissolved in 100 μ l solubilizing buffer and the plates were kept at 25 °C for 2 hours. 
The intensity of the color developed after addition of the solubilizing buffer was measured using Biotek Cytation 
3 spectrophotometer at 570 nm. Viability of the cells transfected with various samples was then calculated by 
considering the untreated cells as 100% viable.
Fluorescence microscopy. To investigate the cellular uptake of TBN, we incubated H23 cells with various 
analogues of the nanoparticle. For simplicity, dyes, Fluorescein (fl) and Cy5 (cy5) functionalized to the corre-
sponding ingredient of the nanoparticle is depicted through subscript. The various analogues are as follows: 
(1) GelflNP-Ab-siRNAcy5, (2) GelflNP-Ab-siRNA, (3) Gel NP-Abcy5-siRNA, (4) Gel NP-Ab-siRNAcy5, (5) siRNAcy5 
and (6) Abcy5. H23 cells were seeded in 6-well plates (5 × 105 cells/well). Cells were grown on a poly-L-lysine 
treated glass coverslip. 100 μ l of each samples (Analogues 1, 2, 3, 4 and 5) were incubated for 4 hours at 37 °C in 
serum free media. After treatment, resulting cover slips were washed with PBS (1X) to remove unbound particles 
and microscopic slides were prepared with DAPI nuclear stain. Slides were imaged using a polarized Dark-field 
fluorescence microscope at 20X magnification.
Western blot analysis. Cells were seeded at a density of 1 × 106 cells/ml and incubated for overnight at 
37 °C in 5% CO2 atmosphere. Nanoparticle and relevant control samples were incubated in serum free media for 
the period of 72 hrs. For control experiments, siRNA transfection (240 nM) was performed using TransIT-X2 
dynamic delivery system transfecting agent (Mirus Bio) as per manufacturer’s instructions. Whole-cell lysates 
were prepared using Triton X 100 lysis buffer with MS-SAFE protease and phosphatase cocktail inhibitor 
(Sigma-Aldrich) and the protein concentration was equalized by Bicinchoninic acid assay (Sigma-Aldrich). 
Proteins were separated by 4–15% native PAGE (Bio-Rad) and were transferred onto nitrocellulose membranes 
(GenScript). Membranes were incubated with primary antibody overnight at 4 °C, were washed and incubated 
with secondary antibody. Primary antibodies used for western blotting are rabbit polyclonal anti-β -actin, rabbit 
monoclonal anti-AKT, rabbit monoclonal anti-phospho-AKT, rabbit polyclonal anti-MEK1/2, rabbit polyclonal 
anti-phospho-MEK1/2, rabbit monoclonal anti-EGFR, rabbit monoclonal anti-phospho-EGFR, rabbit monoclo-
nal anti-SHP2, rabbit polyclonal anti-phospho-SHP2 (Tyr542), rabbit polyclonal anti-phospho-SHP2 (Tyr580), 
rabbit monoclonal anti-phospho-GAB1 (Tyr627), rabbit polyclonal anti-phospho-GAB1 (Tyr307), all from Cell 
Signaling and mouse monoclonal anti-KRAS from Santa Cruz Biotech. The membranes were developed with 
peroxidase-labeled anti-mouse or anti-rabbit IgG (Cell Signaling Tech.) using enhanced chemiluminescence sub-
strate (Pierce) and imaged on Fujifilm LAS-3000 imaging system. Actin protein levels were used as a control for 
adequacy of equal protein loading. Protein expression levels were quantified by densitometry analysis.
In vitro stability studies. An aliquot of each sample containing 75 pmoles of siRNA was analyzed by 4–15% 
polyacrylamide gel electrophoresis (PAGE, BioRad, 100 V for 60 minutes) using Tris borate EDTA running buffer. 
The gels were then stained with GelRed (Thermo Scientific, USA) and imaged using UV trans-illumination light 
filter and image analysis was performed using Biorad Laboratories Image Lab v.3.0.
Animal studies. All animal experiments were approved by the Notre Dame IACUC (approval #14-04-1726) 
and conducted in accordance with Freimann Life Science Center guidelines for human animal treatment. In vivo 
dose safety studies of TBN were performed in normal mice. TBN (80 mg/Kg of body weight) was suspended in PBS 
and administered via tail vein for 3 consecutive days. Animals were monitored for any changes in the behavior. After 
3 days, animals were sacrificed and vital organs collected, tissues fixed in formalin, stained with H&E for histology.
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